ACT Adds Third Clinical Trial Site for Testing Treatment of Dry Macular Degeneration With Embryonic Stem Cells
April 9, 2012
Advanced Cell Technology (OTCBB: ACTC) recently announced that Bascom Palmer Eye Institute had received IRB approval to become the third U.S. clinical site for testing ACT’s human embryonic stem cell-derived retinal pigment epithelial cells in the treatment of dry age-related macular degeneration (dry AMD).
Bascom Palmer, one of the country’s premier eye institutes, joins UCLA’s Jules Stein Eye Institute and the Wills Eye Institute as the third U.S. site participating in the company’s Phase I/II clinical trials.
The Phase I/II trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format.
Click here to learn more about patient eligibility to participate in the trials.
To read more about the trials, please follow this link.
You might also enjoy...
- ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD
- Second Patient With Stargardt’s Macular Dystrophy Treated With Stem Cells in Advanced Cell Technology Trial
- Advanced Cell Technology Obtains FDA Approval to Treat Dry AMD with Embryonic Stem Cells
- Progress Made in Treating Stargardt’s and Dry AMD Using Embryonic Stem Cells
- Register for Regeneron’s Webcast This Coming Sunday, February 13, Providing Update on VEGF Trap-Eye Clinical Studies
Jump down to form below to submit your own comments